During Friday’s Current trade, Shares of Illumina, Inc. (NASDAQ:ILMN), gain 0.87% to $201.68.
Illumina, Inc. (ILMN) declared that it will webcast the Company’s presentation at the Morgan Stanley Global Healthcare Conference in New York on September 17, 2015. The live webcast is planned to start at 2:05 PM ET and will feature an overview of the company by Jay Flatley, Chief Executive Officer, followed by a question and answer session.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The companys products comprise sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms comprise of HiScan and iScan systems, in addition to NextSeq 550 system that are array scanners for DNA and RNA analysis applications, counting single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis.
Shares of Tenet Healthcare Corp (NYSE:THC), declined -1.65% to $46.39, during its current trading session.
Tenet Healthcare Corporation (THC) senior administration will take part in the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 16, 2015 at about 9:20 a.m. EDT.
Tenet Healthcare Corporation, a healthcare services company, primarily operates acute care hospitals and related healthcare facilities in the United States. It operates through two segments, Hospital Operations and Other, and Conifer. The company’s general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP), during its Thursday’s current trading session gained 1.00% to $7.19.
Synergy Pharmaceuticals Inc. (SGYP) declared that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Morgan Stanley Global Healthcare Conference on Friday, September 18th, 2015 at 9:20 a.m. Eastern Time at the Grand Hyatt New York.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, in addition to in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Finally, CYS Investments Inc (NYSE:CYS), gained 1.32%, to $7.67.
CYS Investments, Inc. (CYS) declared that Kevin E. Grant, CFA, the Company’s CEO and President, will deliver a presentation at the JMP Financial Services & Real Estate Conference at the St. Regis Hotel in New York City on Monday, September 21, 2015 at about 9:00 a.m. (ET).
CYS Investments, Inc., a specialty finance company, invests in residential mortgage pass-through securities in the United States. It also focuses on investing in residential mortgage-backed securities that are issued and the principal and interest of which are guaranteed by a federally chartered corporation (Agency RMBS); debt securities issued by the United States Department of Treasury or a government sponsored entity; and collateralized mortgage obligations issued by a government agency or government-sponsored entity that are collateralized by Agency RMBS.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
